Stalevo: Difference between revisions
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[Category: Drugs]][[Category: Catechol-O-methyltransferase inhibitor]] | [[Category: Drugs]][[Category: Dopaminergic Antiparkinsonian agent]][[Category: Catechol-O-methyltransferase inhibitor]] | ||
[[:Category: Antiparkinsonian Drug | '''Antiparkinsonian Drug''']] | [[:Category: Antiparkinsonian Drug | '''Antiparkinsonian Drug''']] | ||
'''Drug class: [[:Category: Catechol-O-methyltransferase inhibitor | Catechol-O- | '''Drug class: [[:Category: Dopaminergic Antiparkinsonian agent | Dopaminergic Antiparkinsonian Agent]]''' and is categorized as a combination of '''[[:Category: Decarboxylase Inhibitors | decarboxylase inhibitors]]''' and '''[[:Category: Catechol-O-methyltransferase inhibitor | Catechol-O-methyltransferase Inhibitor, COMT Inhibitor]]''' | ||
'''Carbidopa | '''Carbidopa, Etacapon and Levodopa (STALEVO)'''(中文:[[始立]]) | ||
==Pronunciation== | ==Pronunciation== | ||
===Stalevo 100mg=== | ===Stalevo 100mg=== | ||
[[File:Stalevo 100mg.mp3]] | [[File:Stalevo 100mg.mp3]] | ||
==Common Strengths of Stalevo== | |||
Stalevo is available in six strengths, each containing a specific ratio of its components: | |||
*Stalevo 50: 12.5 mg carbidopa, 50 mg levodopa, 200 mg entacapone | |||
*Stalevo 75: 18.75 mg carbidopa, 75 mg levodopa, 200 mg entacapone | |||
*Stalevo 100: 25 mg carbidopa, 100 mg levodopa, 200 mg entacapone | |||
*Stalevo 125: 31.25 mg carbidopa, 125 mg levodopa, 200 mg entacapone | |||
*Stalevo 150: 37.5 mg carbidopa, 150 mg levodopa, 200 mg entacapone | |||
*Stalevo 200: 50 mg carbidopa, 200 mg levodopa, 200 mg entacapone | |||
==Drug Trade Name== | |||
The primary trade name for this medication is Stalevo. | |||
==Drug Usage== | |||
Stalevo is used to treat symptoms of Parkinson's disease, including tremors, stiffness, and difficulty with movement. It dose not cure the disease but helps manage its symptoms. | |||
==Mechanism of Action== | |||
Stalevo consists of three active ingredients: carbidopa, levodopa, and entacapone. | |||
The mechanism involves: | |||
*Levodopa converting to dopamine in the brain. | |||
*Carbidopa prevents the premature conversion of levodopa to dopamine outside the brain. | |||
*Entacpone inhibits the COMT enzyme to prolong the effect of levodopa by preventing its breakdown. | |||
==Route of Administration== | |||
Stalevo is administered orally, typically as a film-coated tablet. | |||
==Dosages== | |||
Dosage adjustments depend on individual patient needs and conditions. | |||
==Side Effects== | |||
{| class="wikitable" | |||
!style="text-align: left"| Frequency | |||
!Adverse reactions | |||
|- | |||
| rowspan="3" | '''Common Side Effects | |||
| Nausea | |||
|- | |||
| Dizziness | |||
|- | |||
| Dyskinesia | |||
|- | |||
| rowspan="3" | '''Serious Side Effects | |||
| Neuroleptic Malignant Syndrome (NMS) | |||
|- | |||
| Severe allergic reactions | |||
|- | |||
| Dark discoloration of urine or sweat | |||
|} | |||
==Pharmacokinetics== | |||
The pharmacokinetics of Stalevo show: | |||
*Peak concentrations for carbidopa at approximately 2.5 to 3.4 hours, while entacapone peaks at about 0.8 to 1.2 hours post-administration. | |||
*The duration of action can vary but generally lasts several hours depending on individual metabolism and dosage. | |||
==Drug Precautions== | |||
'''Pregnancy | |||
Stalevo falls under Category C; risks versus benefits should be evaluated before use during pregnancy. | |||
'''Breastfeeding | |||
Caution is advised; consult a healthcare provider regarding risk to the infant. | |||
'''Drug Monitoring Items | |||
Regular monitoring includes: | |||
*Blood pressure checks | |||
*Renal function tests (eGFR) | |||
*Monitoring for dyskinesias or other movement disorders, may occur or worsen with Stalevo. Regular assessments are necessary to determine if dosage adjustments are needed. | |||
*Mental Health Monitoring: Patients should be closely observed for mental changes, including depression and suicidal tendencies. | |||
*Impulse Control Disorders: Patients and caregivers should be informed about the risk of impulse control disorders, which can manifest as compulsive behaviors such as gambling or eating. | |||
*INR Monitoring: For patients on warfarin, monitoring of INR levels is recommended when initiating Stalevo therapy due to potential interaction | |||
'''Drug Interactions | |||
Notable interaction include: | |||
*Contraindications with MAO Inhibitors: Concurrent use with non-selective MAO inhibitors (like phenelzine) can lead to severe hypertension. | |||
*Dopamine Antagonists: Medications such as antipsychotics and antiemetics may reduce the effectiveness of Stalevo. | |||
*Tricyclic Antidepressants: These can increase the risk of hypertension and dyskinesia when used alongside Stalevo. | |||
*Phenytoin and Papaverine: These drugs may diminish the therqpeutic efects of levodopa. | |||
Food interactions: | |||
*High-protein meals can impair the absorption of levodopa. | |||
*Alcohol may exacerbate side effects like dizziness or drowsiness. | |||
==FAQ== | |||
'''How Should I Take the Tablet? | |||
Usually with food to minimize gastrointestinal upset. | |||
'''What Should I Avoid While Taking? | |||
Avoid consuming high-protein meals close to dosing time as they may interfere with the absorption of levodopa. | |||
'''What Happens if I Miss a Dose? | |||
If you miss a dose, take it as soon as you remember unless it is close to the time for your next dose; do not double up on doses. | |||
Latest revision as of 04:23, 14 October 2024
Drug class: Dopaminergic Antiparkinsonian Agent and is categorized as a combination of decarboxylase inhibitors and Catechol-O-methyltransferase Inhibitor, COMT Inhibitor
Carbidopa, Etacapon and Levodopa (STALEVO)(中文:始立)
Pronunciation[edit]
Stalevo 100mg[edit]
Common Strengths of Stalevo[edit]
Stalevo is available in six strengths, each containing a specific ratio of its components:
- Stalevo 50: 12.5 mg carbidopa, 50 mg levodopa, 200 mg entacapone
- Stalevo 75: 18.75 mg carbidopa, 75 mg levodopa, 200 mg entacapone
- Stalevo 100: 25 mg carbidopa, 100 mg levodopa, 200 mg entacapone
- Stalevo 125: 31.25 mg carbidopa, 125 mg levodopa, 200 mg entacapone
- Stalevo 150: 37.5 mg carbidopa, 150 mg levodopa, 200 mg entacapone
- Stalevo 200: 50 mg carbidopa, 200 mg levodopa, 200 mg entacapone
Drug Trade Name[edit]
The primary trade name for this medication is Stalevo.
Drug Usage[edit]
Stalevo is used to treat symptoms of Parkinson's disease, including tremors, stiffness, and difficulty with movement. It dose not cure the disease but helps manage its symptoms.
Mechanism of Action[edit]
Stalevo consists of three active ingredients: carbidopa, levodopa, and entacapone.
The mechanism involves:
- Levodopa converting to dopamine in the brain.
- Carbidopa prevents the premature conversion of levodopa to dopamine outside the brain.
- Entacpone inhibits the COMT enzyme to prolong the effect of levodopa by preventing its breakdown.
Route of Administration[edit]
Stalevo is administered orally, typically as a film-coated tablet.
Dosages[edit]
Dosage adjustments depend on individual patient needs and conditions.
Side Effects[edit]
| Frequency | Adverse reactions |
|---|---|
| Common Side Effects | Nausea |
| Dizziness | |
| Dyskinesia | |
| Serious Side Effects | Neuroleptic Malignant Syndrome (NMS) |
| Severe allergic reactions | |
| Dark discoloration of urine or sweat |
Pharmacokinetics[edit]
The pharmacokinetics of Stalevo show:
- Peak concentrations for carbidopa at approximately 2.5 to 3.4 hours, while entacapone peaks at about 0.8 to 1.2 hours post-administration.
- The duration of action can vary but generally lasts several hours depending on individual metabolism and dosage.
Drug Precautions[edit]
Pregnancy
Stalevo falls under Category C; risks versus benefits should be evaluated before use during pregnancy.
Breastfeeding
Caution is advised; consult a healthcare provider regarding risk to the infant.
Drug Monitoring Items
Regular monitoring includes:
- Blood pressure checks
- Renal function tests (eGFR)
- Monitoring for dyskinesias or other movement disorders, may occur or worsen with Stalevo. Regular assessments are necessary to determine if dosage adjustments are needed.
- Mental Health Monitoring: Patients should be closely observed for mental changes, including depression and suicidal tendencies.
- Impulse Control Disorders: Patients and caregivers should be informed about the risk of impulse control disorders, which can manifest as compulsive behaviors such as gambling or eating.
- INR Monitoring: For patients on warfarin, monitoring of INR levels is recommended when initiating Stalevo therapy due to potential interaction
Drug Interactions
Notable interaction include:
- Contraindications with MAO Inhibitors: Concurrent use with non-selective MAO inhibitors (like phenelzine) can lead to severe hypertension.
- Dopamine Antagonists: Medications such as antipsychotics and antiemetics may reduce the effectiveness of Stalevo.
- Tricyclic Antidepressants: These can increase the risk of hypertension and dyskinesia when used alongside Stalevo.
- Phenytoin and Papaverine: These drugs may diminish the therqpeutic efects of levodopa.
Food interactions:
- High-protein meals can impair the absorption of levodopa.
- Alcohol may exacerbate side effects like dizziness or drowsiness.
FAQ[edit]
How Should I Take the Tablet?
Usually with food to minimize gastrointestinal upset.
What Should I Avoid While Taking?
Avoid consuming high-protein meals close to dosing time as they may interfere with the absorption of levodopa.
What Happens if I Miss a Dose?
If you miss a dose, take it as soon as you remember unless it is close to the time for your next dose; do not double up on doses.
